Aberdeen Group plc Increases Stock Holdings in ADMA Biologics Inc $ADMA
Aberdeen Group plc significantly increased its stake in ADMA Biologics Inc. by 109.9% in the third quarter, now owning 1,116,312 shares valued at $16.365 million. This move is part of a broader trend where institutional investors hold 75.68% of ADMA stock. The biotechnology company has a "Buy" consensus rating from analysts, with an average target price of $28.50.
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Biologics, Inc. announced that it will report its fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and company updates, with registration required for participants. ADMA Biologics is a commercial biopharmaceutical company specializing in manufacturing, marketing, and developing specialty biologics, including FDA-approved plasma-derived products, for immunodeficient patients.
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Biologics, a biopharmaceutical company, announced it will report its fourth-quarter and full-year 2025 financial results on February 25, 2026, after market close. The company's management will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and provide company updates. Investors are encouraged to register for the call or listen to the live webcast.
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Biologics announced it will report its Q4 and full-year 2025 financial results on February 25, 2026, after market close, followed by a conference call at 4:30 p.m. ET. The company specializes in manufacturing and marketing FDA-approved plasma-derived biologics for immunodeficient patients and is developing new products. Recent insider trading shows sales by the CEO, while institutional investors have made significant additions and removals of ADMA shares.
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Biologics, Inc. announced that it will report its fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. The company's management team will host a conference call and audio webcast on the same day at 4:30 p.m. ET to discuss the results and provide company updates. Attendees are encouraged to register for the call or listen to the live webcast, and an archived replay will be available on the investor section of their website.
Adam Grossman, president of Adma Biologics, sells $337,679 in shares
Adam Grossman, President and CEO of ADMA Biologics, recently sold 21,000 shares of the company's common stock for over $337,000. These transactions, executed under a pre-arranged trading plan, occurred after Grossman exercised stock options. Following the sale, his direct and indirect holdings in ADMA Biologics remain substantial, with the company boasting a market cap of approximately $3.8 billion and a positive diluted EPS.
Assessing ADMA Biologics (ADMA) Valuation After Recent Share Price Rebound
ADMA Biologics (ADMA) has seen a recent 3.2% gain after a period of decline and is currently trading at $16.09. According to a discounted cash flow analysis, the stock is considered 23.1% undervalued with a fair value of $20.93, driven by assumptions of rising margins and faster revenue expansion, particularly from high-margin hyperimmunes. Investors are encouraged to build their own narratives and consider the risks associated with reaching assumed revenue scales and margins.
Public Sector Pension Investment Board Acquires 116,867 Shares of ADMA Biologics Inc $ADMA
The Public Sector Pension Investment Board significantly increased its stake in ADMA Biologics Inc. by 14.4% in the third quarter, acquiring an additional 116,867 shares. This purchase brings their total holdings to 930,800 shares, valued at approximately $13.65 million, and reflects strong institutional interest in the biotechnology company. Other major investors, including Royal Bank of Canada and UBS, also increased their positions, signaling confidence in ADMA Biologics which currently holds a "Buy" rating from analysts with a target price of $28.50.
Navellier & Associates Inc. Has $176,000 Stake in ADMA Biologics Inc $ADMA
Navellier & Associates Inc. significantly reduced its stake in ADMA Biologics Inc. by 92.9% in Q3, selling 157,924 shares but still retaining 12,036 shares valued at approximately $176,000. Despite this reduction, institutional ownership in ADMA Biologics remains high at 75.68%, with several large holders making notable position changes. The biotechnology company, specializing in plasma-derived biologics, currently holds a "Buy" consensus rating from analysts with an average target price of $28.50, while its stock trades near $16.28.
New York State Common Retirement Fund Decreases Stock Holdings in ADMA Biologics Inc $ADMA
The New York State Common Retirement Fund significantly reduced its stake in ADMA Biologics Inc. by 63.4% in the third quarter of 2025, selling 198,337 shares and leaving it with 114,504 shares valued at $1.679 million. While other institutional investors like Kornitzer Capital Management increased their holdings, overall institutional ownership in ADMA Biologics stands at 75.68%. The biotechnology company's shares opened at $16.43 with a market cap of $3.91 billion, and analysts maintain an average "Buy" rating with a $28.50 price target.
Principal Financial Group Inc. Cuts Stock Holdings in ADMA Biologics Inc $ADMA
Principal Financial Group Inc. reduced its stake in ADMA Biologics Inc by 14.4% in the third quarter of 2025, selling 223,394 shares and now holding 1,323,041 shares valued at approximately $19.4 million. Despite this reduction, other large institutions like State Street and Thrivent increased their positions, maintaining institutional ownership at about 75.68%. Wall Street analysts generally have a "Buy" rating for ADMA Biologics, with a consensus target price of $28.50, significantly higher than its current trading price of around $16.43.
Renaissance Group LLC Has $7.57 Million Stock Holdings in ADMA Biologics Inc $ADMA
Renaissance Group LLC significantly increased its stake in ADMA Biologics Inc. by 50.4% in the third quarter, bringing its total holdings to 516,588 shares valued at approximately $7.57 million. This move is supported by ADMA Biologics' strong financial performance, including solid Q3 EPS and revenue that exceeded expectations, alongside a "Buy" consensus analyst rating and a target price of $28.50. The biotechnology company, trading at $16.43 with a $3.91 billion market cap, also shows robust institutional ownership.
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in ADMA Biologics Inc $ADMA
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in ADMA Biologics Inc. by 80.1% in Q3, selling 196,326 shares and retaining 48,925 shares. Despite this, other institutions like Royal Bank of Canada and UBS AM increased their holdings. ADMA Biologics reported solid Q3 earnings with $0.16 EPS and $134.22 million in revenue, aligning with analyst estimates.
ADMA Biologics Inc $ADMA Shares Bought by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans significantly increased its stake in ADMA Biologics (NASDAQ:ADMA) by 24.9% in the third quarter, purchasing 826,415 additional shares and now owning 1.74% of the company, valued at $60.72 million. This move comes as ADMA Biologics reported strong financial results, including a 12% year-over-year revenue increase to $134.22 million and an EPS of $0.16, meeting estimates. The company maintains a "Buy" consensus rating from Wall Street analysts with an average price target of $28.50.
A Look At ADMA Biologics (ADMA) Valuation After Strong Analyst Support And Growing Interest In Its Therapies
ADMA Biologics (ADMA) is receiving fresh investor attention due to strong analyst support and growing interest in its plasma-derived therapies, despite a recent short-term share price decline. The company has demonstrated significant long-term returns, and analysts suggest it is undervalued with a fair value estimate of $27.25, significantly higher than its current $16.33 share price. This valuation is based on projected improvements from its FDA-approved yield enhancement process and double-digit revenue growth.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
This article evaluates whether Adma Biologics (ADMA) is a worthwhile investment, considering Wall Street's bullish recommendations. It highlights ADMA's average brokerage recommendation (ABR) of 1.67, indicating a Strong Buy to Buy consensus, with two out of three recommendations being "Strong Buy." However, the article cautions against relying solely on ABRs due to potential analyst bias and instead suggests validating investment decisions with the Zacks Rank, which for ADMA is currently a Zacks Rank #2 (Buy) due to positive earnings estimate revisions.
Kornitzer Capital Management Inc. KS Acquires 312,115 Shares of ADMA Biologics Inc $ADMA
Kornitzer Capital Management Inc. significantly increased its stake in ADMA Biologics Inc. by purchasing an additional 312,115 shares, bringing its total ownership to 359,985 shares valued at $5.277 million. This move reflects a broader trend of institutional investors boosting their positions in ADMA Biologics, with other major funds also increasing their holdings. ADMA Biologics reported solid Q3 financial results with revenue up 12% year-over-year and an average analyst rating of "Buy" with a consensus price target of $28.50.
ADMA Biologics (ADMA) Is Down 5.0% After Expanding Multi-Year Revenue Guidance Targets - Has The Bull Case Changed?
ADMA Biologics expanded its multi-year revenue guidance, raising projections for 2025, 2026, 2027, and 2029, showcasing ambitious growth targets. Despite this positive guidance, the stock fell by 5.0%, and its 1-year return is modest compared to the market, suggesting investors are weighing execution risk with its relatively new management and non-cash earnings. The article implies that while the long-term outlook is stronger, the immediate market reaction reflects skepticism about the company's ability to deliver on these elevated expectations.
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
ADMA Biologics (ADMA) has seen its shares gain 13.8% in the past three months, outperforming the industry and the S&P 500, driven by strong demand for its lead product, Asceniv, and a positive outlook for 2026. The company has increased its 2026 revenue and EBITDA targets and anticipates over $1.1 billion in revenues by fiscal 2029, supported by an expanded plasma supply network and yield-enhanced production. ADMA currently holds a Zacks Rank #2 (Buy), indicating further growth potential.
ADMA Biologics, Inc. (ADMA): A Bull Case Theory
This article summarizes a bullish thesis on ADMA Biologics, Inc. (ADMA), highlighting its strong revenue growth, profitability, and vertically integrated business model in the plasma-derived immunoglobulin therapies sector. Key catalysts include FDA approval for yield-enhanced production and pipeline optionality, with management projecting significant revenue increases in the coming years. While risks like product concentration and competition exist, the company's fundamentals and expanding margins position it as a compelling growth investment.
ADMA Biologics, Inc. (ADMA): A Bull Case Theory
This article summarizes a bullish thesis on ADMA Biologics, Inc. (ADMA), highlighting its position as a differentiated biotech company with strong revenue growth and profitability in plasma-derived immunoglobulin therapies. Key drivers include its vertically integrated model, FDA-approved products, expanding gross margins, and high targets for future revenue, despite risks like product concentration and competition.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
The article evaluates Adma Biologics (ADMA) based on Wall Street analyst recommendations and the Zacks Rank system. While ADMA has an average brokerage recommendation (ABR) suggesting a "Buy," the article cautions against relying solely on these, noting analysts' tendency for positive bias. It highlights the Zacks Rank as a more reliable indicator, which currently gives ADMA a "Hold" rating due to unchanged earnings estimates.
ADMA’s Upgraded Multi‑Year Revenue Targets Might Change The Case For Investing In ADMA Biologics (ADMA)
ADMA Biologics recently upgraded its multi-year revenue guidance, targeting approximately US$510–US$511 million for 2025, US$635 million for 2026, and over US$1.10 billion for 2029, driven by yield-enhanced production and plasma network repositioning. This new outlook may significantly alter the investment case for ADMA, despite ongoing operational risks related to manufacturing. The company's projections suggest substantial revenue and earnings growth, leading to a fair value estimate significantly higher than its current stock price.
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
ADMA Biologics announced preliminary unaudited full-year 2025 revenues of $510-$511 million and raised its 2026 revenue outlook to approximately $635 million, along with an increased adjusted EBITDA guidance of $360 million. The company also provided strong forecasts for 2027 and 2029, expecting revenues over $1.1 billion by 2029, driven by demand for its lead product Asceniv and a more flexible plasma sourcing model. This robust outlook and pipeline development position ADMA favorably in the biotech sector.
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
ADMA Biologics reported strong preliminary unaudited full-year 2025 revenues of $510-$511 million and exited the year with $88 million in cash. The company increased its 2026 revenue outlook to $635 million and adjusted EBITDA to $360 million, driven by demand for Asceniv, margin expansion from yield-enhanced production, and an improved capital-efficient plasma sourcing model. ADMA also provided initial 2027 guidance and projects over $1.1 billion in revenues by 2029, with a new preclinical program, SG-001, offering additional growth potential.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
This article discusses whether Adma Biologics (ADMA) is a good investment, analyzing Wall Street analyst recommendations versus the Zacks Rank system. While ADMA has an average brokerage recommendation (ABR) leaning towards "Strong Buy," the article cautions against relying solely on these ratings due to potential bias. It emphasizes the Zacks Rank, which is based on earnings estimate revisions, as a more reliable indicator for near-term stock price movements, currently assigning ADMA a "Hold" status.
A Look At ADMA Biologics (ADMA) Valuation After New 2025–2027 Guidance And SG-001 Progress
ADMA Biologics (ADMA) has updated its 2025–2027 financial projections, detailing expected revenues, adjusted EBITDA, and margins. The company's stock has seen significant returns, with a 20.07% increase in 90 days, and analysts currently view ADMA as 34.1% undervalued, with a fair value of $27.25 compared to its current $17.95 share price. This valuation is driven by progress in its product pipeline, including SG-001, which is projected to add $300–$500 million in annual revenue.
Infection-fighting drug data powers ADMA Biologics’ big growth plans
ADMA Biologics reported preliminary unaudited FY2025 revenue of $510–511 million and raised its FY2026 revenue target to $635 million and adjusted EBITDA to $360 million, with long-term targets exceeding $1.1 billion in revenue and $700 million adjusted EBITDA by FY2029. The company highlighted successful implementation of yield-enhanced production, strategic plasma network repositioning, and compelling clinical data for its ASCENIV product as key growth drivers. ADMA also plans an FDA pre-IND submission for its SG-001 pipeline program in 2026, which it believes represents a significant annual revenue opportunity.
ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7% - Should You Sell?
ADMA Biologics (NASDAQ:ADMA) saw its stock price drop 8.7% on Monday, trading on lower-than-average volume. Despite this, analysts maintain an average "Buy" rating with a target price of $28.50, although Weiss Ratings reiterated a "hold" view. The company recently reported strong quarterly earnings with $0.16 EPS and revenue of $134.22 million, exceeding consensus estimates.
ADMA - Adma Biologics Latest Stock News & Market Updates
This page provides the latest news and market updates for ADMA Biologics (NASDAQ: ADMA), a biopharmaceutical company specializing in plasma-derived biologics. The content includes financial results, operational milestones, FDA approvals, and future guidance. Recent announcements include strong revenue and EBITDA projections, FDA approval for yield enhancement technology, and plans for pipeline progression, indicating significant growth trajectory and strategic financial management.
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
ADMA Biologics announced preliminary unaudited total revenue of approximately $510-$511 million for full year 2025, meeting or exceeding prior guidance. The company also reiterated its FY 2025 Adjusted EBITDA and Adjusted Net Income guidance, while increasing revenue and Adjusted EBITDA expectations for FY 2026 and FY 2027. ADMA highlighted operational momentum, including yield-enhanced production, strategic plasma network repositioning, and strong demand for ASCENIV™, projecting over $1.1 billion in annual revenue and over $700 million in Adjusted EBITDA by FY 2029.
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
ADMA Biologics announced preliminary unaudited total revenue of $510-$511 million for full-year 2025, meeting or exceeding prior guidance, and reiterated its FY 2025 Adjusted EBITDA and Net Income guidance. The company expects significant revenue and Adjusted EBITDA growth in 2026 and 2027, targeting over $1.1 billion in annual revenue and over $700 million in Adjusted EBITDA by fiscal year 2029. This optimistic outlook is driven by increased ASCENIV demand, strategic plasma network repositioning, yield-enhanced production, and pipeline advancements.
Peregrine Capital Management LLC Purchases 73,868 Shares of ADMA Biologics Inc $ADMA
Peregrine Capital Management LLC increased its stake in ADMA Biologics Inc. by 16.2% during the third quarter, acquiring 73,868 additional shares to own a total of 530,524 shares valued at $7.78 million. Other institutional investors also adjusted their holdings in ADMA Biologics, which reported Q3 EPS of $0.16 and revenue of $134.22 million, and currently holds a "Buy" rating from analysts with an average target price of $28.50.
A Look At ADMA Biologics (ADMA) Valuation As J.P. Morgan Healthcare Conference Presentation Nears
ADMA Biologics (ADMA) has a podium presentation scheduled at the J.P. Morgan Healthcare Conference on January 12, 2026. Despite recent share price declines over the past 7 and 30 days, the stock shows strong multi-year returns. Analysts suggest the stock is undervalued, with a fair value of $27.25 against its current $17.88, based on growth, margin assumptions, and recent debt refinancing.
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
ADMA Biologics will participate in a podium presentation at the J.P. Morgan Healthcare Conference on January 12, 2026, where Adam Grossman, President and CEO, will present. The presentation will be available via live audio webcast on the company's investor relations website. ADMA Biologics is a biopharmaceutical company specializing in plasma-derived biologics for immunodeficient patients.
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
ADMA Biologics, a biopharmaceutical company, announced its President and CEO, Adam Grossman, will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 a.m. PT. A live audio webcast will be available on the company's investor relations website. The company specializes in manufacturing and developing specialty biologics for immune-deficient patients.
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
ADMA Biologics, Inc. announced that its President and CEO, Adam Grossman, will present at the J.P. Morgan Healthcare Conference on January 12, 2026. The company is a U.S.-based biopharmaceutical firm specializing in plasma-derived biologics for immunodeficient patients. A live webcast of the presentation will be available on ADMA's investor relations website.
Why (ADMA) Price Action Is Critical for Tactical Trading
This article analyzes Adma Biologics Inc (NASDAQ: ADMA) price action, indicating weak near and mid-term sentiment but a neutral long-term outlook. It highlights an exceptional 60.6:1 risk-reward setup targeting a 17.6% gain against 0.3% risk. The piece also outlines three distinct AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles.
Allspring Global Investments Holdings LLC Sells 1,772,112 Shares of ADMA Biologics Inc $ADMA
Allspring Global Investments Holdings LLC significantly reduced its stake in ADMA Biologics Inc, selling 1,772,112 shares and cutting its position by 53.4% during the third quarter. Despite this, ADMA Biologics reported solid Q3 results with $0.16 EPS and $134.22 million in revenue, exceeding analyst expectations, and maintains a "Buy" consensus rating with a target price of $28.50. The company, which specializes in plasma-derived biologics, is widely held by hedge funds and institutional investors who collectively own 75.68% of its stock.
ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade
Shares of ADMA Biologics (ADMA) fell 3.7% to $18.40 in afternoon trading, underperforming the broader biotech group, amidst holiday-thin trading conditions and year-end liquidity drying up. This drop occurred after the company reported strong third-quarter revenue and raised its full-year 2025 and 2026 revenue outlooks, with a focus on yield-enhanced manufacturing for margin expansion. The near-term focus for investors is on the company's execution and how increased output translates to sustained margin gains.
Harbor Capital Advisors Inc. Buys Shares of 59,801 ADMA Biologics Inc $ADMA
Harbor Capital Advisors Inc. has acquired 59,801 shares of ADMA Biologics Inc. in the third quarter, valued at approximately $877,000. This move aligns with increased institutional ownership of ADMA, which stands at around 75.7%, and reflects strong financial performance by the biotechnology company including 12% year-over-year revenue growth and a 42.87% net margin. Analysts currently rate ADMA with a "Buy" consensus and an average target price of $28.50.
Rice Hall James & Associates LLC Has $4.75 Million Stake in ADMA Biologics Inc $ADMA
Rice Hall James & Associates LLC significantly reduced its stake in ADMA Biologics Inc by 17.1%, selling 66,962 shares but still retaining 323,653 shares valued at approximately $4.75 million. Despite this, institutional investors collectively own 75.68% of ADMA Biologics. The company reported strong financial results in its last quarter with $0.16 EPS and $134.22 million revenue, leading analysts to maintain a "Buy" rating with a consensus target price of $28.50.
Assessing ADMA Biologics (ADMA) Valuation After Its Upgraded 2025 Revenue Guidance
ADMA Biologics recently raised its 2025 revenue guidance to $510 million, indicating strong growth momentum with a 14% one-month share price return and over 430% total shareholder return in three years. Despite significant past gains, the company is considered approximately 28.1% undervalued with a narrative fair value of $27.25, supported by long-term growth prospects, improved liquidity from debt refinancing, and potential for enhanced free cash flow and EPS. However, its valuation depends on successfully scaling its yield enhancement process and navigating competition and regulation within its specialized IVIG portfolio.
Texas Permanent School Fund Corp Has $1.87 Million Holdings in ADMA Biologics Inc $ADMA
The Texas Permanent School Fund Corp recently decreased its stake in ADMA Biologics Inc. by 39.3%, now holding 102,932 shares valued at approximately $1.87 million. Despite this, other major institutions significantly increased their positions, raising institutional ownership to 75.68%. Analysts maintain a "Buy" rating for ADMA, with a consensus price target of $28.50, following the company's meeting of EPS estimates and a 12% year-over-year revenue increase in its latest quarter.
ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance
ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance, projecting total revenue of $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income modestly to $158 million due to a higher effective tax rate. ADMA Biologics specializes in plasma-derived biologics for immune deficiencies and infectious diseases.
ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance
ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance to $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income to $158 million due to a higher effective tax rate. ADMA Biologics specializes in developing and marketing plasma-derived biologics for immune deficiencies and infectious diseases.
ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance
ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance to $510 million, an increase from the previous guidance of over $500 million. The company also made a modest adjustment to its 2025 adjusted net income, now projected at $158 million, due to a higher effective tax rate. ADMA Biologics is a biopharmaceutical company focused on developing, manufacturing, and marketing plasma-derived biologics for immune deficiencies and infectious diseases.
Perpetual Ltd Cuts Stake in ADMA Biologics Inc $ADMA
Perpetual Ltd significantly reduced its stake in ADMA Biologics Inc by 26.8% during Q3, selling 774,995 shares and retaining 2,119,291 shares valued at approximately $31.07 million. Despite Perpetual Ltd's reduction, institutional investors own about 75.68% of ADMA, and analysts maintain a "Buy" rating with a consensus price target of $28.50. ADMA Biologics recently reported Q3 EPS of $0.16 and revenue of $134.22 million, exceeding analyst expectations, with strong net margins and return on equity.
Does ADMA’s Upgraded EPS Outlook And Higher-Yield Manufacturing Change The Bull Case For ADMA Biologics (ADMA)?
ADMA Biologics recently reported strong quarterly results, increased its 2025 and 2026 earnings guidance, and received FDA approval for a new manufacturing process expected to boost yields by 20%. These developments underpin management's projection for a four-fold increase in EPS by 2030, reinforcing the company's investment narrative. While the new high-yield process offers significant margin expansion potential, its successful large-scale execution is crucial, and any operational setbacks could impact the revised outlook.
Thrivent Financial for Lutherans Raises Stock Holdings in ADMA Biologics Inc $ADMA
Thrivent Financial for Lutherans significantly increased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 78.1% in Q2, now holding 3,315,425 shares valued at over $60 million. This move comes as ADMA Biologics reported strong Q2 earnings, meeting analyst expectations with $0.16 EPS and a 12% revenue increase, alongside robust profitability metrics. Despite a recent downgrade to "hold" by Weiss Ratings, the broader analyst consensus remains a "Buy" with a target price of $28.50.
